Endonovo Reaches Out to Top Clinical Researchers to Collaborate on TBI Treatment Studies
Los Angeles, CA, April 25, 2023 (GLOBE NEWSWIRE) — Endonovo Therapeutics, Inc. (OTCQB:ENDV), a leading developer of medical technologies, today announced it is moving forward in its clinical development in the field of Traumatic Brain Injury (TBI) treatment.
Related news for (ENDV)
- Endonovo Closes Asset Purchase Agreement for a Minimum of $50M With SofPulse, Inc
- Endonovo’s SofPulse® to Be Featured at Innovative Pain Management Solutions
- Endonovo Signs Definitive Agreement to Sell SofPulse® Brand Business and IP to SofPulse Inc. for a minimum of $50 Million
- Endonovo’s SofPulse® Secures Taiwan FDA Approval
- Endonovo’s SofPulse® Secures Federal Supply Schedule Inclusion to Accelerate Expansion of VA Distribution